These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

237 related articles for article (PubMed ID: 19512921)

  • 1. Dyslipidemia of kidney disease.
    Attman PO; Samuelsson O
    Curr Opin Lipidol; 2009 Aug; 20(4):293-9. PubMed ID: 19512921
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Progression of renal failure: role of apolipoprotein B-containing lipoproteins.
    Attman PO; Samuelsson O; Alaupovic P
    Kidney Int Suppl; 1997 Dec; 63():S98-101. PubMed ID: 9407433
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The dyslipidemia of chronic renal disease: effects of statin therapy.
    Ozsoy RC; van Leuven SI; Kastelein JJ; Arisz L; Koopman MG
    Curr Opin Lipidol; 2006 Dec; 17(6):659-66. PubMed ID: 17095911
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Statin treatment for dyslipidemia in chronic kidney disease and renal transplantation: a review of the evidence.
    Kanbay M; Turgut F; Covic A; Goldsmith D
    J Nephrol; 2009; 22(5):598-609. PubMed ID: 19809992
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Alterations of lipid metabolism in chronic nephropathies: mechanisms, diagnosis and treatment.
    Lacquaniti A; Bolignano D; Donato V; Bono C; Fazio MR; Buemi M
    Kidney Blood Press Res; 2010; 33(2):100-10. PubMed ID: 20357496
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Dyslipidemia as a therapeutic target for prevention of cardiovascular events and end-stage renal disease].
    Watanabe T
    Nihon Rinsho; 2008 Sep; 66(9):1761-9. PubMed ID: 18788407
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Chronic kidney disease and statins].
    Matovinović MS
    Lijec Vjesn; 2006; 128(11-12):345-50. PubMed ID: 17212196
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An ABC of apolipoprotein C-III: a clinically useful new cardiovascular risk factor?
    Chan DC; Chen MM; Ooi EM; Watts GF
    Int J Clin Pract; 2008 May; 62(5):799-809. PubMed ID: 18201179
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lipid management in chronic kidney disease, hemodialysis, and transplantation.
    Montague T; Murphy B
    Endocrinol Metab Clin North Am; 2009 Mar; 38(1):223-34. PubMed ID: 19217521
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lipoprotein metabolism and lipid management in chronic kidney disease.
    Kwan BC; Kronenberg F; Beddhu S; Cheung AK
    J Am Soc Nephrol; 2007 Apr; 18(4):1246-61. PubMed ID: 17360943
    [No Abstract]   [Full Text] [Related]  

  • 11. Lipid metabolism in chronic kidney disease: the role of statins in cardiovascular risk.
    Wanner C; Drechsler C; Krane V
    J Ren Nutr; 2007 Jan; 17(1):75-8. PubMed ID: 17198938
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Kidney disease and cardiovascular disease: implications of dyslipidemia.
    Keane WF; Lyle PA
    Cardiol Clin; 2005 Aug; 23(3):363-72. PubMed ID: 16084284
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lipid abnormalities and cardiovascular risk in renal disease.
    Ritz E; Wanner C
    J Am Soc Nephrol; 2008 Jun; 19(6):1065-70. PubMed ID: 18369085
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Apolipoprotein C-III: understanding an emerging cardiovascular risk factor.
    Ooi EM; Barrett PH; Chan DC; Watts GF
    Clin Sci (Lond); 2008 May; 114(10):611-24. PubMed ID: 18399797
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lipid disorders in chronic kidney disease: reverse epidemiology and therapeutic approach.
    Chmielewski M; Carrero JJ; Nordfors L; Lindholm B; Stenvinkel P
    J Nephrol; 2008; 21(5):635-44. PubMed ID: 18949717
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dyslipidemia in chronic kidney disease: an approach to pathogenesis and treatment.
    Tsimihodimos V; Dounousi E; Siamopoulos KC
    Am J Nephrol; 2008; 28(6):958-73. PubMed ID: 18612199
    [TBL] [Abstract][Full Text] [Related]  

  • 17. New insights into lipid metabolism in chronic kidney disease: what are the practical implications?
    Kaysen GA
    Blood Purif; 2009; 27(1):86-91. PubMed ID: 19169024
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Updates on apolipoprotein CIII: fulfilling promise as a therapeutic target for hypertriglyceridemia and cardiovascular disease.
    Zheng C
    Curr Opin Lipidol; 2014 Feb; 25(1):35-9. PubMed ID: 24345989
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Diagnosis and classification of dyslipidemia in renal disease.
    Attman PO; Samuelsson O; Alaupovic P
    Blood Purif; 1996; 14(1):49-57. PubMed ID: 8718566
    [TBL] [Abstract][Full Text] [Related]  

  • 20. HMG CoA reductase inhibitors and renoprotection: the weight of the evidence.
    Romayne Kurukulasuriya L; Athappan G; Saab G; Whaley Connell A; Sowers JR
    Ther Adv Cardiovasc Dis; 2007 Oct; 1(1):49-59. PubMed ID: 19124395
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.